You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
[瑞通認股證牛熊證上市產品銷售部董事 葉文炘] 恆指曾迫近兩萬五、即市較多資金追牛 舜宇跌穿200元關、技資者續開好倉博反彈 恆指N類牛61178 熊68625/ 舜光牛67348 熊53690/ 騰訊牛61525 熊66512
美國國會通過1.2萬億美元基建方案,帶動美股延續升勢,道指隔晚收報36432點,升104點(或0.3%),再創收市新高。恆指昨收報24763點,跌106點(或0.4%)。今早回升近200點,重上24950點之上水平。恆指好倉(牛證及認購權證)昨淨流入逾6500萬港元(下同),恆指淡倉(熊證及認沽權證)同日淨流出逾1700萬元,反映投資者預期港股將見反彈。昨日恆指牛證街貨重貨區為收回價23500至23599點,而熊證街貨重貨區為收回價26000至26099點。 ATMX中昨以美團(03690)跌幅最大,曾挫3.4%,盤中低見267.2元,收市跌幅收窄至2%,報271.2元。雖然股價已回落至10天和20天線以下,但暫守月初低位263.2元。據報紅杉資本中國基金創始及執行合夥人沈南鵬出售美團等數間公司股份,涉及金額約2.15億美元。美團今早曾升近2%,高見276元以上遇阻力,升幅收窄並曾倒跌,10天線得而復失。超過2300萬元在昨日淨流入其輪證好倉,淡倉同日則有逾200萬元淨流出。 中國平安(02318)連跌四個交易日後,昨逆市急彈近4%,收56.2元,升破自上月22日延伸下來的短期下降軌。今早再走高逾1%,徘徊在57元水平。昨分別有逾100萬元和逾60萬元淨流入其好倉和淡倉。 藥明生物(02269)上日一度急瀉9.7%,低見92.05元的逾7個月低位,收挫8.6%於93.1元,是表現最差藍籌,同時連跌第4日,累挫16.9%。藥明生物早前上調今年收入及盈利預測指引,並獲券商唱好為行業首選股份之一,但受高瓴資本在第三季大幅減持同業股份拖累,加上輝瑞口服新冠藥物成效高,使多隻疫苗股捱沽,藥明走勢亦跟隨轉弱。股份今早最多反彈7%,重上99.9元。昨有逾550萬元淨流入其好倉,淡倉則有逾60萬元淨流出。 上周五上揚觸及100天線的舜宇光學(02382),昨略為高開後持續受壓,接連跌破50天、10天、20天線,全日收挫6.9%於206元,蒸發前兩個交易日的累計升幅。有券商近日引述舜宇管理層預期全球智能手機市場按年增長低單位數,較年初預期疲弱,而集團的出貨量指引未變。舜宇今早反覆偏軟,再跌2%,曾低見201元。上日有逾390萬元淨流入其好倉,淡倉則有近160萬元淨流出。 瑞通相關認股證之選擇: 恆指輕微價外、中短期購27087,行使價:27100點,2022年3月到期,實際槓桿:14倍 恆指輕微價外、中短期沽24996,行使價:23600點,2022年2月到期,實際槓桿:11.4倍 美團輕微價外、短期購18785,行使價:313元,2022年1月到期,實際槓桿:7.3倍 美團輕微價外、中短期沽28498,行使價:240元,2022年4月到期,實際槓桿:3.4倍 平保價外、中短期購11417,行使價:66.66元,2022年5月到期,實際槓桿:6.2倍 平保輕微價外、中短期沽26595,行使價:51.88元,2022年3月到期,實際槓桿:5.1倍 藥明輕微價外、中短期購12109,行使價:108元,2022年3月到期,實際槓桿:4.1倍 舜光價外、中短期購29361,行使價:248.88元,2022年4月到期,實際槓桿:4.6倍 舜光價外、中短期沽29375,行使價:169.9元,2022年4月到期,實際槓桿:3.5倍 騰訊輕微價外、中短期購17828,行使價:534.3元,2022年4月到期,實際槓桿:7.1倍 騰訊輕微價外、短期沽25903,行使價:424.8元,2022年1月到期,實際槓桿:8.7倍 比迪貼價、短期購23370,行使價:328.88元,2022年2月到期,實際槓桿:5.7倍 比迪價外、中短期沽29189,行使價:258.88元,2022年4月到期,實際槓桿:3.4倍 瑞通相關牛熊證之選擇: 恆指N類牛證61178,收回價及行使價:24360點,槓桿比率:41.4倍 恆指熊證68625,收回價:25300點,槓桿比率:36倍 美團牛證61160,收回價:250.08元,槓桿比率:10.1倍 美團熊證66509,收回價:288.88元,槓桿比率:11.3倍 平保牛證60258,收回價:53元,槓桿比率:12.5倍 平保熊證66508,收回價:61元,槓桿比率:9.2倍 藥明牛證68645,收回價:81.88元,槓桿比率:4.7倍 藥明牛證59271,收回價:88.88元,槓桿比率:6.8倍 藥明熊證68648,收回價:105元,槓桿比率:9.6倍 舜光牛證67348,收回價:180元,槓桿比率:7.5倍 舜光熊證53690,收回價:230元,槓桿比率:5.5倍 騰訊牛證61525,收回價:440元,槓桿比率:14.6倍 騰訊熊證66512,收回價:506.8元,槓桿比率:9.8倍 騰訊熊證66061,收回價:491.8元,槓桿比率:14.1倍 比迪牛證67360,收回價:283.08元,槓桿比率:7.6倍 比迪牛證68656,收回價:292.88元,槓桿比率:9.9倍 比迪熊證57564,收回價:358元,槓桿比率:5.9倍 重要風險通知 本結構性產品並無抵押品。 結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。 閣下投資前應了解產品風險,如有需要應諮詢專業建議。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account